ArticleFuture science OA2025
Chylothorax as a rare complication of COVID-19: a case report.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chylothorax is an uncommon cause of pleural effusion, most often associated with malignancy, trauma, or thoracic duct obstruction. Its occurrence following SARS-CoV-2 infection is exceptional. The present case report describes a 53-year-old woman who was admitted to the pneumology department complaining of chronic dry cough with a medical history of type II diabetes and SARS-CoV-2 infection one month ago. Physical examination revealed decreased vesicular breath sounds at the left lung base. A chest X-ray revealed a left pleural effusion and thoracentesis confirmed chylothorax. This case highlights chylothorax as a rare but possible complication of COVID-19, potentially caused by inflammation and thoracic duct disruption in the absence of thrombosis. It emphasizes the importance of considering chylothorax in the differential diagnosis of unexplained pleural effusions following SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.